Urine Test for Lung Cancer: NHS Breakthrough in 5 Years
Baca dalam 60 detik
- Current trials show the biosensor distinguishes between malignant and benign lung nodules with remarkable precision.
- This could replace costly CT scans and reduce unnecessary biopsies.
- Early detection remains the single most effective strategy to reduce lung cancer mortality, which claims over 35,000 UK lives annually.
The test identifies specific protein fragments shed by lung tumors, detectable in urine samples before symptoms appear. Current trials show the biosensor distinguishes between malignant and benign lung nodules with remarkable precision. This could replace costly CT scans and reduce unnecessary biopsies.
Early detection remains the single most effective strategy to reduce lung cancer mortality, which claims over 35,000 UK lives annually. The urine test's simplicity allows deployment in GP surgeries and community clinics, bypassing hospital bottlenecks. NHS England projects the test could save ยฃ50 million yearly by catching cases earlier.
Researchers now seek funding for large-scale clinical trials across 10 UK hospitals, targeting 5,000 patients. Regulatory approval from MHRA and NICE could fast-track adoption within the five-year timeline. Manufacturing partnerships with diagnostic firms are already under discussion to ensure scalable production.
Power Move: This urine test could dismantle lung cancer's deadly advantage: late detection. If trials succeed, the NHS gains a powerful triage tool that prioritizes high-risk patients for immediate imaging. Expect fierce competition among diagnostics companies to license this technology.
This article was edited with AI assistance for readability. Read original here.
